Cancer Cell Biology

You have full text access to this OnlineOpen article

Pyrazolo–pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling

  1. Sandra Donnini1,†,
  2. Martina Monti1,†,
  3. Cinzia Castagnini1,†,
  4. Raffaella Solito1,†,
  5. Maurizio Botta2,†,
  6. Silvia Schenone3,†,
  7. Antonio Giachetti1,†,
  8. Marina Ziche1,†,‡,*

Article first published online: 27 NOV 2006

DOI: 10.1002/ijc.22410

Issue

International Journal of Cancer

International Journal of Cancer

Volume 120, Issue 5, pages 995–1004, 1 March 2007

Additional Information

How to Cite

Donnini, S., Monti, M., Castagnini, C., Solito, R., Botta, M., Schenone, S., Giachetti, A. and Ziche, M. (2007), Pyrazolo–pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int. J. Cancer, 120: 995–1004. doi: 10.1002/ijc.22410

Author Information

  1. 1

    Dipartimento di Biologia Molecolare, Università degli Studi di Siena, Via Aldo Moro, 2, 53100, Siena, Italy

  2. 2

    Dipartimento Farmaco Chimico Tecnologico, Università degli Studi di Siena, Via Aldo Moro, 2, 53100, Siena, Italy

  3. 3

    Dipartimento Scienze Farmaceutiche, Università degli Studi di Genova, Viale Benedetto XV, 16132 Genova, Italy

  1. †

    This publication reflects only the authors' views. The Commission is not liable for any use that may be made of information herein.

  2. ‡

    Fax +39-0577-234343.

*Department of Molecular Biology, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy

Publication History

  1. Issue published online: 19 JAN 2007
  2. Article first published online: 27 NOV 2006
  3. Manuscript Accepted: 14 SEP 2006
  4. Manuscript Received: 23 MAY 2006

Funded by

  • Italian Ministry for Research. Grant Number: 2004065317_003
  • EU project EICOSANOX FP6 funding. Grant Number: LSHM-CT-2004-005033
  • NuGO. Grant Number: FOOD-CT-2004-506360

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (957K)

References

  • 1
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31.
  • 2
    Frame CM. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002; 1602: 114–30.
  • 3
    Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 1997; 13: 513–607.
  • 4
    Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337–58.
  • 5
    Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, Grandis JR. Src family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004; 64: 6166–73.
  • 6
    Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridhara L, Boghaert E, Arndt K, Ye F, Boschelli DH, Li F, Titsch C et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005; 65: 5358–64.
  • 7
    Brunton VG, Avizienyte E, Fincham VJ, Serrels B, Metcalf CA,III, Sawyer TK, Frame MC. Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behaviour. Cancer Res 2005; 65: 1335–45.
  • 8
    Lesslie DP, Summy JM, Parikh NU, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ, Ellis LM, Gallick GE. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 2006; 94: 1710–17.
  • 9
    Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000; 100: 293–6.
  • 10
    Criscuoli ML, Nguyen M, Eliceiri BP. Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. Blood 2005; 105: 1508–14.
  • 11
    Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915–24.
  • 12
    Weis S, Cui J, Barnes L, Cheresh D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004; 167: 223–9.
  • 13
    Hood JD, Frausto R, Kiosses WB, Schwartz MA, Cheresh DA. Differential αv integrin-mediated ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003; 162: 933–43.
  • 14
    Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ, Sheppard D, Cheresh DA. Src-mediated coupling of focal adhesion kinase to integrin αvβ5 in vascular endothelial growth factor signalling. J Cell Biol 2002; 157: 149–59.
  • 15
    He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-Src. J Biol Chem 1999; 274: 25130–5.
  • 16
    Fulton D, Church JE, Ruan L, Li C, Sood SG, Kemp BE, Jennings IG, Venema RC. Src kinase activates endothelial nitric oxide synthase by phosphorilating tyr-83. J Biol Chem 2005; 280: 35943–52.
  • 17
    Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 107: 2625–34.
  • 18
    Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD, Gallick GE. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 1998; 273: 1052–7.
  • 19
    Laird AD, Li G, Moss KG, Blake RA, Broome MA, Cherrington JM, Mendel DB. Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphoryilation and vascular endothelial growth factor signalling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther 2003; 2: 461–9.
  • 20
    Schenone S, Bruno O, Bondavalli F, Ranise A, Mosti L, Menozzi G, Fossa P, Donnini S, Santoro A, Ziche M, Manetti F, Botta M. Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line. Eur J Med Chem 2004; 39: 939–46.
  • 21
    Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 2003; 9: 5358–69.
  • 22
    Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998; 273: 4220–6.
  • 23
    Morbidelli L, Ziche M. The rabbit corneal pocket assay for the study of angiogenesis. Cancer Treat Res 2004; 117: 147–51.
  • 24
    Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor- blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001; 61: 5090–101.
  • 25
    Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P, Grassi J, Neri D et al. Selective targeted delivery of TNFα to tumor blood vessels. Blood 2003; 102: 4384–92.
  • 26
    Abram CL, Courtneidge A. Src family tyrosine kinases and growth factor signaling. Exp Cell Res 2000; 254: 1–13.
  • 27
    Biscardi JS, Ishizawar RC, Silva CM, Parson SJ. Tyrosine kinase signalling in breast cancer epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000; 2: 203–10.
  • 28
    Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakesperare WC, Wang Y, Sundaramoorthi R, Metcalf CA,III, Keats JA, Sawyer TK, Gallick GE. AP23846, a novel highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 2005; 12: 1900–11.
  • 29
    Inoue S, Branch CD, Gallick GE, Chada S, Ramesh R. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther 2005; 4: 707–15.
  • 30
    Waltenberger J, Uecker A, Kroll J, Frank H, Mayr U, Bjorge JD, Fujita D, Gaviz A, Hombach V, Levitzki A, Bohmer FD. A dual inhibitor of platelet derived growth factor β-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells: a novel candidate for prevention of vascular remodelling. Circ Res 1999; 85: 12–22.
  • 31
    Kilkenny DM, Rocheleau JV, Price J, Reich MB, Miller GG. C-Src regulation of fibroblast growth factor-induced proliferation in murine embryonic fibroblasts. J Biol Chem 2003; 278: 17448–54.
  • 32
    Rafiee P, Heidemann J, Ogava H, Johnson NA, Fisher PJ, Li MS, Otterson MF, Johnson CP, Binion DJ. Cyclosporin A differentially inhibits multiple steps in VEGF induced angiogenesis in human microvascular endothelial cells through altered intracellular signalling. Cell Commun Signal 2004; 2: 3.
  • 33
    Breslin JW, Pappas PJ, Cerveira JJ, Hobson RW, Duran WN. VEGF increases endothelial permeability by separate signalling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 2003; 284: H92–H100.
  • 34
    Recchia I, Rucci N, Festuccia C, Bologna M, Mackay AR, Migliaccio S, Longo M, Susa M, Fabbro D, Teti A. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motilità and invasion of prostate cancer cells in vitro. Eur J Cancer 2003; 39: 1927–35.
  • 35
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CPN. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinases type 9 production. Clin Cancer Res 2002; 8: 2714–24.
  • 36
    Bishop AC, Ubersax JA, Petsch DJ, Matheos DP, Grey NS, Blethrow J, Shimizu E, Tsien JZ, Schultz PG, Rose MD, Wood JL, Morgan DO et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000; 407: 395–401.
  • 37
    Tatton L, Morley GM, Chopra R, Khwaja A. The Src-selective kinase inhibitor PP1 also inhibits Kit and Brc-Abl tyrosine kinases. J Biol Chem 2003; 278: 4847–53.
View Full Article (HTML) Get PDF (957K)